Filing Flows › Fennec Pharmaceuticals (FENC) › Q2 2026 › vs Q2 2025
Fennec Pharmaceuticals (FENC) Q2 2026 vs Q2 2025 (year over year)
Fennec Pharmaceuticals's revenue rose $8.2M (+85%) from $9.7M in Q2 2025 to $17.9M in Q2 2026. The biggest changes: PEDMARK product sales, net +$7.5M (+78%). Operating margin 9.7% against -28.3% (+38.0 pts).
Fennec Pharmaceuticals, Q2 2026: revenue $17.9M (+85% year over year), operating margin 9.7%, net earnings $2.0M, operating cash flow $50K. The chart draws each line against Q2 2025, the increases inside each band.
Margins
| Q2 2026 | Q2 2025 | Change | |
|---|---|---|---|
| Operating margin | 9.7% | -28.3% | +38.0 pts |
| Net margin | 11.0% | -32.7% | +43.7 pts |
Every line
| Line | Q2 2026 | Q2 2025 | Change | % |
|---|---|---|---|---|
| PEDMARK product sales, net | $17.2M | $9.7M | $7.5M | +78% |
| Revenue | $17.9M | $9.7M | $8.2M | +85% |
| Other income, net | $278K | −$420K | $698K | — |
| Operating profit | $1.7M | −$2.7M | $4.5M | — |
| Costs & expenses | $16.1M | $12.4M | $3.8M | +30% |
| Pre-tax earnings | $2.0M | −$3.2M | $5.2M | — |
| Research & development | $118K | $107K | $11K | +10% |
| Sales & marketing | $10.7M | $4.8M | $5.9M | +123% |
| General & admin | $4.6M | $6.5M | −$1.9M | -29% |
| Other operating costs | $721K | $967K | −$246K | -25% |
| Net earnings | $2.0M | −$3.2M | $5.1M | — |
| Income tax | $42K | $0 | $42K | — |
| Operating cash sources | $3.7M | −$1.7M | $5.4M | — |
| Share-based compensation | $1.8M | $1.5M | $280K | +19% |
| Working capital & other | $3.7M | $2.0M | $1.7M | +82% |
| Operating cash flow | $50K | −$3.7M | $3.7M | — |
Questions
How much did Fennec Pharmaceuticals's revenue grow year over year in Q2 2026?
Fennec Pharmaceuticals's revenue rose $8.2M (+85%) from $9.7M in Q2 2025 to $17.9M in Q2 2026.
What drove Fennec Pharmaceuticals's revenue change in Q2 2026?
PEDMARK product sales, net +$7.5M (+78%).